|
"ryoo b y"的相關文件
顯示項目 21-32 / 32 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目
| 國立成功大學 |
2021 |
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study
|
Harding, J.J.;Yang, T.-S.;Chen, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Ho, C.-L.;Huang, W.-T.;El, Dika I.;Akce, M.;Tan, B.;Cohen, S.A.;Meyer, T.;Sarker, D.;Lee, D.-W.;Ryoo, B.-Y.;Lim, H.Y.;Johnston, A.;Bomalaski, J.S.;O’Reilly, E.M.;Qin, S.;Abou-Alfa, G.K. |
| 臺大學術典藏 |
2020-05-25T07:35:06Z |
An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma
|
Abou-Alfa G.K.;Yau T;Ryoo B.-Y;Knox J;Brown J;Kelley R.K;Chao T.-Y;Choi H.J;Freilich B;Modiano M;Yoon J.-H;Chia-Chi Lin;Yong W.P;Lim H.Y;El Dika I; El Dika I; Lim H.Y; Yong W.P; Chia-Chi Lin; Yoon J.-H; Modiano M; Freilich B; Choi H.J; Chao T.-Y; Kelley R.K; Brown J; Knox J; Ryoo B.-Y; Yau T; Abou-Alfa G.K. |
| 臺大學術典藏 |
2020-05-25T07:35:00Z |
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1�V4, as a single dose and multiple doses in patients with solid malignancies
|
Yamamoto N; Ryoo B.-Y; Keam B; Kudo M; Chia-Chi Lin; Kunieda F; Ball H.A; Moran D; Komatsu K; Takeda K; Fukuda M; Furuse J; Morita S; Doi T. |
| 臺大學術典藏 |
2020 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; CHIH-HUNG HSU; Yen Y.; Tabernero J.; Shen Y.-C.; Hsu C.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Cheng A.-L.; Martinelli E.; Chen L.-T.; Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Hsu C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chih-Hung Hsu;Yoshino T.;Douillard J.-Y.; Choo S.P.; Ho G.F.; Lim H.-Y.; Ikeda M.; Bhattacharyya G.S.; Qin S.; Pentheroudakis G. |
| 國立成功大學 |
2020 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen, L.-T.;Martinelli, E.;Cheng, A.-L.;Pentheroudakis, G.;Qin, S.;Bhattacharyya, G.S.;Ikeda, M.;Lim, H.-Y.;Ho, G.F.;Choo, S.P.;Ren, Z.;Malhotra, H.;Ueno, M.;Ryoo, B.-Y.;Kiang, T.C.;Tai, D.;Vogel, A.;Cervantes, A.;Lu, S.-N.;Yen, C.-J.;Huang, Y.-H.;Chen, S.-C.;Hsu, C.;Shen, Y.-C.;Tabernero, J.;Yen, Yen Y.;Hsu, C.-H.;Yoshino, T.;Douillard, J.-Y. |
| 國立成功大學 |
2018 |
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
|
Abou-Alfa, G.K.;Qin, S.;Ryoo, B.-Y.;Lu, S.-N.;Yen, C.-J.;Feng, Y.-H.;Lim, H.Y.;Izzo, F.;Colombo, M.;Sarker, D.;Bolondi, L.;Vaccaro, G.;Harris, W.P.;Chen, Z.;Hubner, R.A.;Meyer, T.;Sun, W.;Harding, J.J.;Hollywood, E.M.;Ma, J.;Wan, P.J.;Ly, M.;Bomalaski, J.;Johnston, A.;Lin, C.-C.;Chao, Y.;Chen, L.-T. |
| 國立成功大學 |
2018 |
Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular Carcinoma
|
Lim, H.Y.;Merle, P.;Weiss, K.H.;Yau, T.;Ross, P.;Mazzaferro, V.;Blanc, J.-F.;Ma, Y.T.;Yen, C.J.;Kocsis, J.;Choo, S.P.;Sukeepaisarnjaroen, W.;Gerolami, R.;Dufour, J.-F.;Gane, E.J.;Ryoo, B.-Y.;Peck-Radosavljevic, M.;Dao, T.;Yeo, W.;Lamlertthon, W.;Thongsawat, S.;Teufel, M.;Roth, K.;Reis, D.;Childs, B.H.;Krissel, H.;Llovet, J.M. |
| 國立成功大學 |
2018 |
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study
|
Chau, I.;Park, J.O.;Ryoo, B.-Y.;Yen, C.-J.;Poon, R.;Pastorelli, D.;Blanc, J.-F.;Kudo, M.;Pfiffer, T.;Hatano, E.;Chung, H.C.;Kopeckova, Kopeckova K.;Phelip, J.-M.;Brandi, G.;Ohkawa, S.;Li, C.-P.;Okusaka, T.;Hsu, Y.;Abada, P.B.;Zhu, A.X. |
| 國立成功大學 |
2018 |
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
|
Yen, C.-J.;Kim, T.-Y.;Feng, Y.-H.;Chao, Y.;Lin, D.-Y.;Ryoo, B.-Y.;Huang, D.C.-L.;Schnell, D.;Hocke, J.;Loemb�, A.-B.;Cheng, A.-L. |
| 國立成功大學 |
2015-09 |
Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment
|
Chau, I.; Park, J. O.; Ryoo, B. Y.; Yen, C. J.; Poon, R.; Pastorelli, D.; Blanc, J. F.; Kudo, M.; Pfiffer, T. F.; Hatano, E.; Chung, H. C.; Kubackova, K.; Phelip, J. M.; Brandi, G.; Ohkawa, S.; Li, C. P.; Okusaka, T.; Yang, L.; Abada, P.; Zhu, A. |
| 國立成功大學 |
2015-06-01 |
Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma
|
Palmer, D.; Meyer, T.; Chao, Y.; Deptala, A.; Fartoux, L.; Feng, Y. -H.; Graham, J.; Lin, D. -Y.; Ma, Y. T.; Peck-Radosavljevic, M.; Ross, P.; Ryoo, B. -Y.; Yen, C. -J.; Hocke, J.; Vlassak, S.; Wenz, A.; Loembe, A. -B.; Cheng, A. -L. |
| 國立成功大學 |
2013-09 |
Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomised Phase II trial
|
Yen, C.;Kim, T. Y.;Feng, Y. H.;Chao, Y.;Lin, D. Y.;Studeny, M.;Hocke, J.;Huang, D. C. L.;Ryoo, B. Y.;Cheng, A. L. |
顯示項目 21-32 / 32 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目
|
